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Abstract 29 
Gene expression profiling signatures may be used to classify the subtypes of MDS 30 
patients. However, there are few reports on the global methylation status in MDS. The 31 
integration of genome-wide epigenetic regulatory marks with gene expression levels 32 
would provide additional information regarding the biological differences between MDS 33 
and healthy controls. Gene expression and methylation status were measured using 34 
high-density microarrays. A total of 552 differentially methylated CpG loci were 35 
identified as being present in low-risk MDS; hyper-methylated genes were more 36 
frequent than hypo-methylated genes. In addition, mRNA expression profiling identified 37 
1005 genes that significantly differed between low-risk MDS and the control group. 38 
Integrative analysis of the epigenetic and expression profiles revealed that 66.7% of 39 
the hyper-methylated genes were under-expressed in low-risk MDS cases. Gene 40 
network analysis revealed molecular mechanisms associated with the low-risk MDS 41 
group, including altered apoptosis pathways. The two key apoptotic genes BCL2 and 42 
ETS1 were identified as silenced genes. In addition, the immune response and miRNA 43 
biogenesis were affected by the hyper-methylation and under-expression of IL27RA 44 
and DICER1. Our integrative analysis revealed that aberrant epigenetic regulation is a 45 
hallmark of low-risk MDS patients and could play a central role in these diseases. 46 
 47 
Keywords: gene expression profile, methylation, low-risk MDS, apoptosis, BCL2, 48 
ETS1 transcription factor targets.  49 
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Introduction 50 
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal myeloid stem 51 
cell disorders affecting mainly elderly patients. MDS are characterized by cytopenia of 52 
the peripheral blood (PB), hypercellularity of the bone marrow (BM) and morphological 53 
alterations in one or more hematopoietic cell lineages (1). According to the WHO 54 
classification, MDS can be classified as low- or high-risk depending on the percentage 55 
of blast cells in the BM (2). In most cases, the presence of cytogenetic aberrations, 56 
such as alterations on chromosomes 5, 7, and 8, are the hallmark of MDS, but other 57 
abnormalities in signal transduction, transcription activity, cell-cycle control, 58 
mitochondrial DNA, angiogenesis and epigenetic changes have also been associated 59 
with MDS (3). 60 
 61 
DNA methylation is an epigenetic process that involves the addition of a methyl group 62 
(CH3) to the 5-position carbon of the cytosine pyrimidine ring in a CpG dinucleotide. 63 
This process is carried out in an orchestrated reaction that includes DNA 64 
methyltransferases, methyl-binding domain proteins, and histone deacetylases (4). 65 
DNA cytosine methylation is the best characterized epigenetic event leading to the 66 
stabilization of the genome, the remodeling of the chromatin and the regulation of gene 67 
transcription (5;6). In addition, not only the presence of epigenetic marks but also their 68 
location and density play a crucial role in regulating these processes (7;8). A close 69 
correlation between DNA hyper-methylation and transcriptional silencing has been 70 
established in many  systems (9).  71 
 72 
Epigenetic alterations are now accepted as having a role in carcinogenesis. DNA 73 
hyper-methylation in cancer is associated with the silencing of tumor-suppressor 74 
genes, whereas hypo-methylation has been described as playing a causal role in 75 
progressive tumor formation and in promoting chromosomal instability (5;7;9-11). 76 
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Tumor suppressors are not the only genes affected by aberrant methylation; 77 
abnormally methylated genes with other functions are also subject to silencing in 78 
human cancer, including those involved in DNA repair, apoptosis, angiogenesis, cell 79 
cycle regulation and cell-to-cell interaction (12). Hence, epigenetic modifications in 80 
promoter and/or regulatory regions that lead to transcriptional silencing of genes and 81 
development of cancer are important events requiring to be studied in any onco-82 
pathological state and they are attractive therapeutic targets. 83 
 84 
Gene expression profiling studies have been performed in MDS with the aim of 85 
identifying genes and biological pathways of relevance in these diseases (13;14). 86 
These studies have identified gene expression signatures distinguishing specific 87 
subgroups of MDS and have helped improve our understanding of the biology of these 88 
diseases (15). However, the molecular pathogenesis of MDS is still not fully 89 
understood. Moreover, only part of the cellular information is present at the mRNA 90 
level, and transcriptional activity is dependent on many factors, including epigenetic 91 
modifications. Nevertheless, the methylation patterns of genes have not been as well 92 
explored in low-risk MDS as in other hematopoietic malignancies, and most epigenetic 93 
studies have focused on the analysis of a few tumor suppressor genes (16).  94 
 95 
The underlying mechanisms of altered DNA methylation in low-risk MDS and the target 96 
genes affected by methylation remain unknown. To gain insight into the knowledge of 97 
the molecular mechanisms present in low-risk MDS, an integrative study of methylation 98 
and gene expression profiles was carried out. In this report, we identify genes with 99 
reduced levels of expression in response to increased methylation levels in nearby 100 
CpG islands. Overall, we highlight candidate DNA methylation changes associated with 101 
MDS that may warrant further investigation as potential clinical targets. 102 
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Materials and Methods 103 
Samples collection and cell separation 104 
A total of 83 low-risk MDS patients and 36 age-matched controls without 105 
haematological malignancies were included in the study (Supplementary Table 1). 106 
MDS were classified according to the World Health Organization (WHO) criteria (2). 107 
Mononuclear cells were isolated from BM samples of low-risk MDS patients and 108 
controls by density gradient (Ficoll). A cohort of 18 patients with low-risk MDS and 109 
seven controls were included in a simultaneous integrative study of methylation and 110 
expression, while the whole series was used as a control group of expression data. 111 
The study was approved by the Local Ethical Committees and written informed consent 112 
was obtained from each patient.  113 
 114 
DNA and RNA isolation 115 
Genomic DNA from subject samples was isolated using a DNeasy blood and tissue kit, 116 
following the manufacturer’s protocol. DNA was eluted in AE buffer (Qiagen, Hilden, 117 
Germany).  118 
Total RNA from cells was extracted by homogenization in TRIZOL (Invitrogen, 119 
Carlsbad, CA, USA), following the manufacturer’s protocol, then treated with RQ1 120 
RNAse-Free DNase (Promega, Madison, USA) to eliminate genomic DNA 121 
contamination, and finally purified with RNeasy Minikit (Qiagen). The quantity and 122 
quality of the RNA were determined with an Agilent 2100 Bioanalyzer (Santa Clara, 123 
CA, USA). 124 
 125 
Methylation CpG island amplification and microarray studies (MCAM) 126 
Methylated CpG Island Amplification and Microarray (MCAM) is a two-color array 127 
technique that quantifies methylation by hybridizing equimolar amounts of subject 128 
versus control DNA to an array (17). The University Health Network human 12K CpG 129 
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microarray (UHN, Toronto, Canada) contains 12,192 CpG island clones. Each clone 130 
can be annotated with up to three gene symbols, depending on whether the CpG site 131 
lies upstream, downstream or within the gene. The methylation assay was done largely 132 
as described previously (17), but with the following modifications: DNA was purified 133 
after double digestion, methylated CpG amplification (MCA) reaction and labeling were 134 
done using the QIAquick PCR purification kit (Qiagen) without any indicator in the 135 
buffer PB. RMCA primers (Eurogentec, Southampton, UK) were used at ligation and 136 
MCA reaction stages. The MCA reaction was performed using 5 U HotStarTaq+ 137 
(Qiagen) and samples were aliquoted without primers before being heated to 82 °C. 138 
The primers were held at 95 °C for 1 min before adding 4 μL to each tube. Cycling 139 
conditions were: 95 °C for 10 min before 30 cycles of 95 °C for 1 min, 65 °C for 90 s, 140 
72 °C for 2 min, and finally 72 °C for 10 min, and before holding at 4 °C. Samples were 141 
hybridized to UHN HCGI12K CpG microarrays. After hybridization, microarrays were 142 
washed as follows: 3 × 15 min at 55 °C with wash 1 in a rotating oven, then on a 143 
gyrating platform 2 × 3 min at room temperature (R.T.) 1x SSC, 2 × 3 min at R.T. Wash 144 
2: 2 × 3 min at R.T. 0.1 × SSC, 2 × 3 min at R.T. Millipore H2O. Finally, slides were 145 
rinsed with H2O and centrifuged for 7 min at 370 g to dry. They were scanned with an 146 
Axon GenePix 4400A scanner (MDS Analytical Technologies, Molecular Devices, 147 
Sunnyvale, CA, USA) using Genepix Pro 7 software (MDS Analytical Technologies).  148 
 149 
Bioinformatic analysis  150 
The output GPR files from Gene Pix Pro 7.15 were imported into the R/Bioconductor 151 
Marray program and quality control diagnostic plots were generated and assessed. 152 
Poor-quality arrays were removed from the analysis and repeated. The log ratio of 153 
median red (Cy5-labeled subject sample) to median green (Cy3-labeled universal 154 
control) processed (dye-normalized) signal intensities were computed using the LIMMA 155 
R/Bioconductor program. Probes that had been flagged by Gene Pix Pro 7.15 as bad, 156 
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absent or not found were removed. A genomic smoothing step was then performed in 157 
which a weighted average across 1000 bp was calculated for each CpG clone. In order 158 
to determine the degree of enrichment, the Partek Genomics Suite ANOVA tool was 159 
used and the n-fold change using the geometric mean (for log-transformed data). 160 
Probesets that differed significantly (p < 0.10) between the low-risk MDS and control 161 
groups were selected for further analysis. 162 
 163 
Gene expression microarray studies 164 
Gene expression profiling (GEP) studies were done as part of the Microarray 165 
Innovations in LEukemia (MILE) study (18). GeneChips Human Genome U133 Plus 2.0 166 
arrays (Affymetrix, High Wycombe, UK) are gene expression arrays containing 54,613 167 
oligonucleotide probesets that map onto 18,950 human gene loci, following gene-168 
based remapping of the probes (19). Labeling and hybridization were performed 169 
according to protocols from Affymetrix. Briefly, 100 ng of total RNA was amplified and 170 
labeled using the GeneChip two-cycle cDNA synthesis kit and GeneChip IVT labeling 171 
kit (Affymetrix Inc.) and then hybridized to the Human Genome U133 Plus 2.0 172 
microarray, after quality checking on GeneChips Test3 Arrays. Washing and scanning 173 
were done using Fluidics Station 400 and GeneChip Scanner (Affymetrix Inc.). In 174 
addition, the Human Exon 1.0 ST microarrays (Affymetrix) were used in the study. 175 
 176 
Bioinformatic analysis  177 
The Robust Microarray Analysis (RMA) algorithm was applied to the raw data from the 178 
expression arrays to carry out background correction, intra- and inter-normalization, 179 
and to calculate the expression signal (20). The Significant Analysis of Microarrays 180 
(SAM) algorithm was used to identify genes with statistically significant changes in 181 
expression between different classes (21). For this differential expression analysis, 182 
samples were permuted over 100 cycles using the two-class (unpaired) and multiclass 183 
© 2012 Macmillan Publishers Limited. All rights reserved
    8 
 
response format, considering variances not to be equal for the genes. Significant genes 184 
were selected on the basis of the false discovery rate (FDR), which was used to correct 185 
the p-values, assuming an FDR threshold of <0.15, which allowed better overlap with 186 
the data from the methylation study. To select each gene, the p-values of the statistical 187 
tests were transformed to q-values using the FDR threshold indicated. All the 188 
calculations described here were done using R and Bioconductor. 189 
 190 
Real-Time PCR 191 
To validate the GEP results, the expression levels of four selected genes were 192 
analyzed by RT-PCR. First-strand cDNA was generated from 1 µg of total RNA using 193 
poly-dT as primers with the M-MLV reverse transcriptase (Promega). Real-time PCR 194 
was performed in triplicate. Each 20μl reaction contained 300ng of cDNA, 400 nM of 195 
each primer, and 1x iQ SybrGreen Supermix (Bio-Rad, Hercules, CA, USA). Standard 196 
curves were run for each transcript to ensure exponential amplification and to rule out 197 
non-specific amplification. The expression level of the glyceraldehyde-3-phosphate 198 
dehydrogenase (GAPDH) gene was used to normalize differences in input cDNA. The 199 
reactions were run on an iQ5 Real-Time PCR detection system (Bio-Rad, Hercules, 200 
CA, USA). The primers were designed for specific sequences (Supplementary Table 2) 201 
and checked with the BLAST algorithm (22). In addition, to measure miRNA-145 and 202 
miRNA-196 expression levels, TaqMan qRT-PCR miRNA assay (Applied Biosystem, 203 
Carlsbad, California) was performed. The relative expression levels normalized to 204 
RNU43 endogenous control was determined using the 2−ΔCt method. Each 205 
measurement was performed in duplicate.  206 
 207 
Pyrosequencing 208 
Primers were designed for forward, reverse and sequencing using the PyroMark Assay 209 
Design 2.0 program. Primer sequences can be found in Supplementary Table 3. 210 
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Bisulfite conversion of DNA was done as described by Frommer et al (23). The hot-211 
start polymerase chain reaction (PCR) was carried out using 2μL (50ng) of bisulfite-212 
treated DNA. PCR was performed following the manufacturer’s instructions. 213 
Pyrosequencing was carried out using the Q24 System (Qiagen), also in accordance 214 
with the manufacturer's protocols. 215 
 216 
Integrative functional analysis of methylation and expression data 217 
To analyze the functional enrichment of the selected gene lists we used the DAVID 218 
bioinformatic resource (http://david.abcc.ncifcrf.gov/) (24) and the web-delivered 219 
bioinformatics tool set IPA (Ingenuity Pathway Analysis 9.0; http://www.ingenuity.com). 220 
These tools allow the identification of functional modules and the most relevant 221 
biological processes present in the gene lists performing statistical enrichment analysis 222 
based on contingency tests. The Metacore Analytical Suite (Genego Inc., St. Joseph, 223 
MI, USA) was also used for the network analysis of some of the initial data from 224 
differentially methylated/expressed genes. Metacore’s shortest path algorithm was 225 
applied to derive a network for the selected genes. Biological processes enriched in 226 
differentially methylated/expressed gene lists were identified and p-values determined 227 
using Metacore’s enrichment analysis workflow. 228 
The common transcription factor binding sites (TFBSs) were analyzed using search 229 
tools that allowed the sequences upstream of the genes of a given query list to be 230 
explored, for the purpose of finding significant candidate promoter regions. These tools 231 
search for sequence profiles similar to the TFBS defined in JASPAR 232 
(http://jaspar.cgb.ki.se/). The bioinformatic tools used were: oPOSSUM 233 
(http://www.cisreg.ca/cgi-bin/oPOSSUM/opossum) (25); TransFind (http://transfind.sys-234 
bio.net/index.php/home.html) (26); Pscan (http://159.149.109.9/pscan/) (27); and TFM-235 
Explorer (http://bioinfo.lifl.fr/cgi-bin/TFME/tfme.py) (28). 236 
 237 
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Results 238 
Low-risk MDS and normal BM have distinct DNA methylation profiles 239 
The methylation profiles of low-risk MDS patients were compared with those of controls 240 
using the 12K CpG array. Statistically significant changes in the level of CpG island 241 
methylation were identified. A total of 552 CpG loci were sufficiently differentially 242 
methylated between the two groups to give a value of p < 0.10. These loci were 243 
associated with 817 annotated gene symbols: 457 genes were hyper-methylated in 244 
low-risk MDS, and 360 genes were hypo-methylated. The median fold changes were 245 
1.85 (7.82 to 1.09) and -1.65 (-4.73 to -1.11), respectively (Supplementary Table 4). 246 
The three most representative cellular functions for genes commonly altered by 247 
methylation were GM-CSF signaling (e.g., LYN, GNB2L1 and ZNF225), apoptosis-248 
HTR1A signaling (e.g., BCL2 and MAP2K1) and TGF-beta-dependent induction of 249 
EMT via SMADs (e.g., SMAD2, HN1 and CDH2). In addition, four of the top ten cellular 250 
functions deregulated by methylation were related to the immune response (Table 1). 251 
Amongst the genes involved in this response, IL27RA and CD28 were hyper-252 
methylated whilst IL6 and CD96 were hypo-methylated in MDS patients. 253 
 254 
Gene expression profiling distinguishes low-risk MDS from normal BM 255 
The GEP from the BM of low-risk MDS patients was compared with that from the BM of 256 
healthy individuals. 1975 genes showed significant differences (FDR cut-off < 0.15) in 257 
mRNA expression levels between the two groups: 764 were over-expressed whilst 258 
1211 genes were under-expressed in low-risk MDS (Supplementary Table 5). This 259 
number was reduced to 1005 genes when an FDR cut-off of < 0.10 (444 up-regulated 260 
and 561 down-regulated genes) was applied. These genes were selected for further 261 
investigation. Hierarchical clustering, selecting for differentially expressed genes, 262 
resulted in a good separation of the two groups analyzed, except in three patients 263 
(Figure 1). These samples had a less differential profile although they were distinct 264 
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from the controls. Interestingly, two of them displayed chromosomal alterations that 265 
were not present in any other patients: a loss on 5q and a monosomy 7. The most 266 
over-expressed gene in low-risk MDS (R.fold=8.08) was GDF15, which has a role in 267 
regulating inflammatory and apoptotic pathways during disease processes. By contrast, 268 
cellular development, post-translational modification and the cell-mediated immune 269 
response were the most frequently deregulated molecular and cellular functions 270 
(Supplementary Figure 1). In addition, cellular growth and proliferation was the function 271 
involving the largest group of genes: 121 molecules, of which BCL2, ETS1 and FLT3 272 
were highlighted as down-regulated genes in MDS patients (Supplementary Table 5). It 273 
should be noted that nucleosome assembly,  chromatin organization and DNA 274 
packaging were also significant functions that were altered in low-risk MDS. In this 275 
respect, a total of 33 up-regulated histone genes involved in these three functions were 276 
observed in low-risk MDS (Supplementary Table 5).  277 
 278 
Hyper-methylation correlates with decreased gene expression in low-risk MDS 279 
An integrative approach involving methylation and expression profiling was used to 280 
characterize genomic changes between low-risk MDS patients and healthy controls. 281 
Comparison of the 817 putative target genes of differential methylation and the 1975 282 
genes of differential expression allowed the detection of gene loci that experienced 283 
both concurrent changes in low-risk MDS patients. In total, 91 genes were both 284 
differentially methylated and differentially expressed (Figure 2A): 37 of these (41%) 285 
were hypo-methylated, and 54 (59%) were hyper-methylated (Figure 2B). Thirteen of 286 
the genes that were hypo-methylated in low-risk MDS also featured up-regulated gene 287 
expression (35%), all with a value of p < 0.10 in both the methylation and expression 288 
analyses. UBE2D3, ING1 and RRAS2 were highlighted in this group of genes (Table 289 
2). 290 
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Interestingly, a high proportion (66.7%) of hyper-methylated genes was also down-291 
regulated (all with a value of p < 0.10 in the methylation and expression analyses). This 292 
combination represented the highest association between methylation and expression 293 
with respect to the other possible combinations and was consistent with the pattern 294 
expected for silenced genes. For this reason, this group of 36 genes was examined 295 
further (Figure 2B; Table 3). Using functional enrichment, we observed that the most 296 
well represented categories in this gene set were regulation of gene expression, RNA 297 
process, immune response, regulation of cell differentiation, and cell adhesion and 298 
apoptosis (Figure 3). Finally, we externally validated the most significant genes for the 299 
top altered functions: regulation of gene expression (ETS1), RNA process (DICER1), 300 
the immune response (IL27RA) and apoptosis (BCL2). The under-expression of these 301 
genes was confirmed in the larger cohort of 83 MDS patients by expression arrays 302 
(Supplementary Figure 2). In addition, the differential methylation and expression of all 303 
four genes from the integrative group was confirmed by pyrosequencing and Q-PCR, 304 
respectively, and there was a 100% correlation between these techniques and the 305 
previous results.  306 
 307 
Hyper-methylation of the ETS1 transcription factor is linked to gene down-308 
regulation in low-risk MDS 309 
As ETS1 is a transcription factor, we explored the link between the hyper-methylation 310 
of the transcription factor and the down-regulation gene observed in low-risk MDS 311 
patients. For this purpose, we analyzed the promoter regions of the 561 genes included 312 
in the under-expression signature assigned to low-risk MDS (Table 4). We searched for 313 
the TFBSs within this set of 561 genes. The analysis demonstrated that the ETS1 314 
transcription factor, which is hyper-methylated and under-expressed in low-risk MDS, is 315 
involved in regulating 83 target genes included in the down-regulation signature of 316 
these MDS patients. The most significant functions of these target genes were 317 
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delineated and the cell-to-cell signaling and interaction pathway were found to be 318 
prominently affected. The genes included in this function were FOXP1, ITGAL, ZAP70 319 
and LCK (Table 4). In addition, cell death (apoptosis) was identified as the function with 320 
greatest number of down-regulated target genes (IL7R, ITGAL, LCK, MAP4K1, PAK2, 321 
PTAFR, TNFSF13, TOPBP1 and TRADD) (Table 4).  322 
 323 
DICER1-interacting genes are deregulated in low-risk MDS patients 324 
The identification of DICER1 as a gene that is quite significantly altered by methylation 325 
and expression in low-risk MDS prompted us to investigate other genes involved in 326 
RNA processing and related to DICER1.  ATXN1, NFE2L3 and POP4 proved to have 327 
direct genetic interactions with DICER1. ATXN1 was under-expressed in low-risk MDS 328 
cases while NFE2L3 and POP4 were hyper-methylated and under-expressed in this 329 
group of patients (Table 3 and Supplementary Table 5). Moreover, PIWIL4, which was 330 
down-regulated in the low-risk MDS group, was involved in protein-protein interactions 331 
with DICER1. Interestingly, POP4 and PIWIL4 had genetic interactions with the 332 
RNASE4 gene. This gene was under-expressed in low-risk MDS patients 333 
(Supplementary Table 5). In addition, to analyze the effect of the DICER1 deregulation, 334 
183 miRNAs expression levels were measured. A general down-regulation of miRNAs 335 
was observed in low-risk MDS cases respect to the control group (Wilcoxon p value: 336 
0.039) (Supplementary Figure 3). However, no significant differences in miRNA-145 337 
and miRNA-196 expression between low-risk MDS and controls were observed. 338 
 339 
IL27RA and other immune response-related genes are down-regulated in low-risk 340 
MDS patients 341 
An immune response-related analysis was carried out to compare low-risk MDS 342 
patients with the control group. This study showed that three genes involved in the 343 
histocompatibility complex (HLA-DQB1, HLA-DQA1 and HLA-DPB1) were down-344 
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regulated in low-risk MDS. We also found that besides IL27RA, which was hyper-345 
methylated and under-expressed in MDS, another nine interleukins and interleukin 346 
receptors were under-expressed in the same cohort of patients: IL16, IL32, IL1RAP, 347 
IL2RB, IL6R, IL7R, IL10RA, IL10RB and IL13RA1 (Supplementary Table 5). Three of 348 
them (IL16, IL1RAP and IL10RB) had direct genetic interactions with IL27RA.  349 
 350 
Hyper-methylation of BCL2 leads to under-expression of the gene and increased 351 
apoptosis in low-risk MDS 352 
The significant alteration of expression and methylation pattern of BCL2 observed in 353 
low-risk MDS patients suggests a deregulation of the control of apoptosis. The genetic 354 
and epigenetic signatures of apoptosis-related genes in this group of patients were 355 
studied. BCL2L11 and MYC were found to be over-expressed in low-risk MDS patients; 356 
in contrast, BAX and CUX1 were under-expressed in this group of patients with respect 357 
to the control group. In addition, the SYK gene, which was hyper-methylated and 358 
under-expressed, was also associated with apoptosis and BCL2. In addition, we 359 
integrated all these genes in a simple interaction network to reveal the links and 360 
associations between them (Figure 4). 361 
 362 
 363 
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Discussion 364 
Aberrant methylation is a potential mechanism for inactivating genes that has been 365 
implicated in several hematological malignancies, including MDS (29;30). 366 
Nevertheless, until now we have not known whether the low-risk MDS cases have a 367 
specific and distinct DNA methylation profile, as has been demonstrated for the gene 368 
expression profile (GEP) (15;31). The present study showed that the low-risk MDS 369 
patients had a different methylation profile involving 817 genes. Moreover, the GEP 370 
study displayed a deregulation of cellular development and post-translational 371 
modification genes in low-risk MDS patients. It should be noted that, in addition to 372 
these cellular functions, our analysis, performed in mononuclear cells, corroborated the 373 
mainly deregulated functions previously described in the GEP analysis of CD34+ cells, 374 
such as cellular proliferation (15) and up-regulation of histones involved in nucleosome 375 
organization (31). It is of particular note that GDF15, which was previously described 376 
as being deregulated in RARS patients (32), was the most over-expressed gene in low-377 
risk MDS patients.  378 
 379 
Only a few reports concerning MDS have established a connection between 380 
methylation and expression, and most of these epigenetic studies have focused on the 381 
analysis of a small number of tumor suppressor genes. For this reason, our study 382 
aimed to carry out a combined analysis of the methylation and the GEPs in low-risk 383 
MDS patients. To our knowledge, this is the first time the same cohort of patients has 384 
been used to analyze both profiles in MDS. The integrative study identified DNA 385 
methylation markers that could lead to the down-regulation of some genes involved in 386 
important cellular functions in low-risk MDS: BCL2, ETS1, IL27RA and DICER1.  387 
 388 
MDS are characterized by ineffective hematopoiesis that results in peripheral blood 389 
cytopenias, despite the hypercellular dysplasia in bone marrow. Previous studies 390 
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suggested that the increased apoptosis of the bone marrow myeloid precursors is an 391 
important factor in the ineffective hematopoiesis of MDS patients. These studies also 392 
showed that the increased programmed cell death probably represents a 393 
pathophysiological mechanism rather than a compensatory process to counteract 394 
increased cell growth (31;33;34). Members of the BCL2 family are major regulators of 395 
these apoptotic pathways. The present study shows that BCL2 expression was 396 
significantly weaker in mononuclear low-risk MDS cells than in normal individuals. 397 
These results are in accordance with previous studies that showed reduced BCL2 398 
expression in CD34+ cells of patients with early MDS subtypes (35). Furthermore, our 399 
study showed that BCL2 had significantly higher methylation levels in low-risk MDS 400 
samples. Consistent with the increasing evidence for a fundamental role of epigenetic 401 
silencing of apoptotic pathways in cancer (36-38), the hyper-methylation and the 402 
inverse correlation of mRNA expression of BCL2 would be expected to promote 403 
apoptosis in MDS patients. The under-expression of BCL2 in low-risk MDS due to 404 
aberrant methylation deserves further investigation as a low-risk MDS biomarker and 405 
supports a role for apoptosis-targeted therapy in these patients in the future. 406 
 407 
Our study found hyper-methylation and under-expression of the ETS1 gene in the 408 
same group of low-risk MDS patients compared with the control group. Several studies 409 
have indicated that the level of ETS expression is reduced during tumorigenesis. These 410 
analyses show that ETS1 suppresses tumorigenicity and the cases with a high level of 411 
ETS1 expression had better outcomes for disease-free survival than those with a low 412 
level (39). These findings suggest that under-expression of ETS1 could have a crucial 413 
role in tumor promotion in MDS patients, especially during their early phases. ETS1 is 414 
a nuclear phosphoprotein that functions as a transcription factor by binding the target 415 
DNA sequences containing a central GGAA/T core motif (ETS-binding site, EBS) (40). 416 
The ETS protein influences the expression of genes that are involved in various 417 
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biological processes, including hematopoiesis, cellular proliferation, differentiation, 418 
development, transformation and apoptosis (41). Over 400 ETS1 target genes have 419 
been defined to date, based upon the presence of functional EBS in their regulatory 420 
regions (41). To investigate whether a decrease in ETS1 expression in low-risk MDS 421 
patients had a functional effect, the expression levels of ETS1 target genes were 422 
examined and a significant difference in the level of expression of 83 target genes in 423 
the patient group relative to control group was observed. Likewise, several other 424 
studies have demonstrated co-expression of ETS factors and presumptive ETS target 425 
genes in solid tumors (42-44). 426 
 427 
Several approaches have been used to demonstrate that ETS and/or the genetic 428 
pathways that this gene regulates could be potential targets for therapy. In addition, the 429 
methylation and decreased expression of ETS1 has been involved in silencing several 430 
genes during cellular senescence (45). Therefore, ETS1 deregulation could be related 431 
to cellular senescence. In the same study, the mRNA expression levels of ETS1 in the 432 
senescent cells increased significantly with the 5-aza-2′- deoxycytidine treatment. 433 
These findings could partially explain the response to 5-aza-2′-deoxycytidine treatment 434 
in MDS patients as a result of the possible induction of ETS1. 435 
 436 
Apoptosis was the most widely affected function, with nine down-regulated ETS1 437 
targets. The overall apoptosis pathway could be affected in low-risk MDS patients in 438 
two ways: (1) methylation and decreased expression of BCL2 with the deregulation of 439 
related genes (BCL2L11, MYC, BAX, CUX1 and SYK), and (2) methylation and 440 
decreased expression of the ETS1 transcription factor with the deregulation of its 441 
apoptosis-related targets. The molecular basis of apoptosis in MDS is largely unknown 442 
and comprehensive characterization of epigenetic disruption of apoptosis-related 443 
genes in MDS cases is lacking. For this reason, these findings may shed some light on 444 
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this matter. In addition, a clearer understanding of the molecular events leading to the 445 
deregulation of cell death in MDS should allow us to identify therapeutic targets and 446 
diagnostic markers. 447 
 448 
IL27RA is a component of the heterodimeric complex receptor IL27R that is involved in 449 
immunosuppression by inducing a signal transduction in response to IL27 (46). Our 450 
studies identified a marked difference in IL27RA methylation levels between low-risk 451 
MDS patients and healthy controls that may be responsible for the under-expression 452 
shown by these patients. These results are consistent with recent studies in which 453 
IL27RA has been shown to be a promoter of hematopoietic stem cell differentiation, 454 
which appears to enhance myelopoiesis in a transgenic mouse system (46). According 455 
to this, down-regulation of IL27RA could lead to the ineffective differentiation of 456 
hematopoietic progenitors already described in MDS patients by other authors (33). 457 
Moreover, animal models with defects in IL27 or its receptor (IL27RA) display 458 
enhanced immune responses in a range of infectious and noninfectious situations (47). 459 
Therefore, our results are also consistent with these features and with the deregulation 460 
of the immune response known in MDS (33). Furthermore, immune response 461 
deregulation could be enhanced in low-risk MDS patients due to the genetic 462 
interactions between IL27RA and IL16, IL1RAP and IL10RB, and the lower level of 463 
expression of histocompatibility complex genes. 464 
 465 
DICER1 is an RNase III endonuclease essential for microRNA (miRNA) biogenesis and 466 
RNA processing (48). Altered miRNA expression can be expected to occur as a result 467 
of variations in pre-miRNA processing by DICER1. Fluctuations in miRNA expression 468 
regulate the expression of key tumor suppressor genes and oncogenes (49) and the 469 
fate of hematopoietic cells (48). Their global deregulation by the under-expression of 470 
DICER1 promotes tumorigenesis. Reduced DICER1 expression has been associated 471 
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with multiple solid neoplasias (49). In the current study, we observed that DICER1 472 
expression levels were widely lower in patients with low-risk MDS. In addition, DICER1 473 
was hyper-methylated in low-risk MDS, which could be responsible for the DICER1 474 
under-expression observed in these patients. A deletion in DICER1 has been recently 475 
described in osteoprogenitors that impairs osteoblastic differentiation and the integrity 476 
of hematopoiesis and induces bone marrow dysfunction with myelodysplasia (48). 477 
These data suggest that the disruption of DICER1 by methylation or mutation may 478 
cause myelodysplasia in mice resembling important features of human MDS. Our 479 
findings also showed that DICER1 had direct genetic interactions with ATXN1, NFE2L3 480 
and POP4 deregulated genes, which might affect the normal relationship of these 481 
genes with DICER1 and consequently the deregulation of the functions in which they 482 
are involved. Furthermore, our data showed an overall slight down-regulation of 483 
miRNAs in low-risk MDS (p-value = 0.039) which could be related to the deregulation 484 
of DICER1. However, no significant differences were found for two miRNAs (miRNA-485 
145 and miRNA-196) that were examined individually. 486 
 487 
Recent advances have suggested a potential role for hyper-methylation in cancer 488 
because of the transcriptional silencing (50). Nevertheless, global DNA hypo-489 
methylation in cancer may be as frequent as hyper-methylation (51). Our study showed 490 
that ING1, UBE2D3 and RRAS2 genes were hypo-methylated and over-expressed in 491 
low-risk MDS patients. The ING1 and UBE2D3 genes are both related to p53. The 492 
ING1 gene encodes a protein that can induce cell growth arrest and apoptosis by 493 
cooperating with p53, and UBE2D3 functions in the ubiquitination of p53. RRAS2, 494 
previously described as being up-regulated by other authors (33), may play an 495 
important role in activating signal transduction pathways that control cell proliferation. 496 
Thus, the alteration of these three genes could be implicated in functions previously 497 
described as deregulated in MDS (15;33). 498 
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In summary, we have generated a DNA methylation profile for low-risk MDS patients 499 
that could extend our knowledge of these diseases. RNA expression levels were 500 
analyzed and correlated with methylation status, suggesting that DNA hyper-501 
methylation events in low-risk MDS are biologically important for gene functions such 502 
as gene expression, RNA processes, the immune response and apoptosis. In addition, 503 
these epigenetic modifications that lead to transcriptional silencing of genes are 504 
attractive therapeutic targets for demethylating agents. 505 
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Figure Legends 713 
Figure 1. GEP of low-risk MDS patients and normal bone marrow samples. The 714 
heatmap shows hierarchical clustering of 1005 genes differentially expressed between 715 
low-risk MDS and control patients. This gene-set was obtained for an FDR cut-off < 716 
0.10 and included 444 upregulated genes and 561 down-regulated genes. The 717 
absolute expression signal obtained for each gene in each sample is represented by a 718 
color scale. Green indicates upregulation and red indicates down-regulation, black 719 
being the intermediate signal. Each row represents a single gene and each column 720 
corresponds to a separate patient sample. The distances in the clustering are based on 721 
Pearson correlation coefficients, calculated pair-wise, using the expression signature of 722 
each gene in all samples. The unique low-risk MDS cases that displayed chromosomal 723 
alterations are showed with a color point: blue for a loss on 5q and orange for a 724 
monosomy 7 725 
 (GEP: gene expression profile; MDS: myelodysplastic syndrome) 726 
 727 
Figure 2. Integrative epi/genomic analysis of low-risk MDS patients compared 728 
with controls. A. Total number of differentially expressed and methylated genes in 729 
low-risk MDS and healthy controls. 91 differentially methylated genes were also 730 
deregulated. B. Quantification of genes identified in a two-way analysis. Bars represent 731 
the differentially methylated genes and the two colors within each bar indicate the 732 
number of differentially expressed genes. The hyper-methylation and under-expression 733 
combination corresponds to the most frequent association between the two analyses 734 
with respect to the other possible combinations. 735 
(MDS: myelodysplastic syndrome) 736 
 737 
Figure 3. Functional analysis of hyper-methylated and under-expressed genes in 738 
low-risk MDS patients. Identification of processes significantly enriched in the hyper-739 
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methylation and under-expression profile of low-risk MDS subjects compared with 740 
control cases. The functional enrichment of the selected genes was analyzed using 741 
DAVID, IPA and Metacore bioinformatics tools. The most representative biological 742 
processes with the highest number of genes are included. The best represented 743 
category was "Regulation of gene expression", which involves 15 genes. 744 
(MDS: myelodysplastic syndrome) 745 
 746 
Figure 4. Schematic representation of the deregulated BCL2-related pathway in 747 
low-risk MDS patients. Red and green respectively denote gain and loss of 748 
expression in the low-risk MDS group relative to control subjects. The yellow genes 749 
BCL2 and SYK were hyper-methylated and under-expressed in low-risk MDS, while 750 
BCL2L11 and MYC were over-expressed and BAX and CUX1 were under-expressed in 751 
the low-risk MDS patients with respect to the control group. An arrow pointing from A to 752 
B signifies that A causes B to be activated. Union between molecules shows protein-753 
protein interactions which occur when two or more proteins bind together, often to carry 754 
out their biological functions. Many of the most important molecular processes in the 755 
cell are carried out by a large number of protein components organized by their protein-756 
protein interactions. Solid and dashed lines respectively indicate direct and indirect 757 
interactions between molecules. The gene network was generated with the Ingenuity 758 
bioinformatics tool. 759 
(MDS: myelodysplastic syndrome) 760 
 761 
 762 
 763 
 764 
 765 
 766 
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Table 1. Most representative cellular functions corresponding to the 817 genes 
deregulated by methylation in low-risk MDS patients. 
   
Cellular Function p-Value 
Development_GM-CSF signaling 5,867E-07 
Apoptosis and survival_HTR1A signaling 0,000007751
Development_TGF-beta-dependent induction of EMT via SMADs  0,00001066 
Development_VEGF signaling and activation 0,00003635 
Development_Regulation of epithelial-to-mesenchymal transition (EMT) 0,00004061 
Transcription_CREB pathway 0,00004159 
Immune response_CD137 signaling in immune cell 0,00005866 
Immune response_Inflammatory response 0,00006636 
Immune response_Histamine H1 receptor signaling in immune response 0,00006889 
Immune response_Histamine signaling in dendritic cells 0,00008708 
 767 
 768 
Table 2. Integration analysis of hypo-methylated and over-expressed genes in low-risk MDS patients.  
             
Expression Methylation 
Gene Symbol 
 d-Value  p-Value  R.Fold Genomic Coordinates CpG Position  p-Value  Fold Change 
CDH4 4,61 0,000 1,22 chr20:59839134-59839709 within 0,057 -1,95 
RAB8B 4,52 0,000 1,70 chr15:61235998-61237132 downStream 0,052 -2,58 
UBE2D3 3,4 0,004 1,18 chr4:104009407-104010129 upStream 0,080 -1,43 
ING1 3,19 0,006 1,37 chr13:110249836-110250880 upStream 0,080 -1,52 
TBPL1 2,91 0,011 1,49 chr6:134258454-134259172 downStream 0,050 -2,96 
CYB5D1 2,84 0,012 1,22 chr17:7702645-7702833 within 0,043 -1,77 
FADS2 2,75 0,015 1,26 chr11:61394615-61395519 upStream 0,008 -2,09 
HCN3 2,72 0,016 1,18 chr1:153500080-153500610 downStream 0,006 -4,29 
H2AFJ 2,59 0,020 1,40 chr12:14847117-14848131 upStream 0,049 -1,88 
RRAS2 2,57 0,021 1,43 chr11:14242512-14242599 downStream 0,019 -2,73 
SYN3 2,56 0,022 1,22 chr22:31900470-31901416 upStream 0,020 -1,61 
AAAS 2,53 0,023 1,29 chr12:52001203-52001932 within 0,040 -1,44 
FXYD2 2,50 0,024 1,19 chr11:117021453-117021806 downStream 0,064 -1,45 
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Table 3. Integration analysis of hyper-methylated and down-expressed genes in low-risk MDS patients. 
       
Expression Methylation Gene Symbol 
 d-Value p-Value  R.Fold Genomic Coordinates CpG Position  p-Value  Fold Change
PLAGL1 -4,96 0,000 0,48 chr6:144457997-144458742 downStream 0,029 1,91 
BCL2 -4,95 0,000 0,74 chr18:59137439-59137855 within 0,039 1,37 
NELL2 -4,82 0,000 0,39 chr12:43649424-43649603 downStream 0,008 2,12 
DICER1 -4,70 0,000 0,45 chr14:94304731-94304947 upStream 0,070 1,46 
NFE2L3 -4,46 0,000 0,78 chr7:25868518-25868873 upStream 0,075 1,62 
IL27RA -3,97 0,001 0,65 chr19:14046138-14046802 downStream  0,043 2,16 
ALCAM -3,95 0,001 0,57 chr3:106555109-106555818 upStream 0,079 1,98 
OPN3 -3,88 0,001 0,58 chr1:239850696-239850953 within 0,008 2,55 
IER3IP1 -3,86 0,001 0,67 chr18:43041077-43041115 downStream 0,030 3,25 
BNIP2 -3,70 0,002 0,70 chr15:58079608-58080222 downStream 0,093 1,36 
RPS6KA5 -3,65 0,002 0,58 chr14:90398496-90398580 upStream 0,009 1,66 
SCP2 -3,60 0,003 0,62 chr1:53291314-53291693 downStream 0,084 1,42 
PTPRC -3,40 0,004 0,69 chr1:198277915-198278316 downStream 0,004 2,43 
CHML -3,33 0,004 0,63 chr1:239850696-239850953 upStream 0,008 2,55 
ZNF33A -3,27 0,005 0,64 chr10:38422763-38423049 downStream 0,087 2,22 
ETS1 -3,14 0,007 0,69 chr11:127896681-127897162 within 0,054 2,29 
GNS -3,06 0,008 0,67 chr12:63700546-63700923 downStream 0,098 1,65 
NPHP3 -3,05 0,008 0,68 chr3:134240338-134240638 downStream 0,059 1,94 
ZNF37A -2,91 0,010 0,80 chr10:38422763-38423049 upStream 0,087 2,22 
NSMCE1 -2,74 0,015 0,80 chr16:27237492-27237759 downStream 0,064 4,37 
RHOU -2,73 0,015 0,59 chr1:227321939-227322103 downStream 0,060 1,57 
CNOT6L -2,70 0,016 0,69 chr4:78960590-78961293 downStream 0,050 2,78 
RPL36AL -2,69 0,017 0,86 chr14:49134842-49136086 upStream 0,059 7,82 
KIAA1128 -2,57 0,021 0,78 chr10:87813066-87813308 downStream 0,011 1,51 
ENC1 -2,49 0,025 0,70 chr5:73973356-73973603 downStream 0,051 2,31 
MAP2K1 -2,48 0,025 0,69 chr15:64436285-64436471 upStream 0,014 1,60 
KLHL8 -2,41 0,029 0,68 chr4:88375883-88376244 downStream 0,014 1,75 
CENTD1 -2,36 0,033 0,63 chr4:31377103-31377307 upStream 0,071 2,09 
PH-4 -2,34 0,034 0,85 chr3:48932150-48932615 upStream 0,070 1,49 
FVT1 -2,33 0,034 0,80 chr18:59137439-59137855 upStream 0,039 1,37 
CD28 -2,30 0,037 0,87 chr2:204053785-204053871 upStream 0,062 2,02 
CHIT1 -2,24 0,041 0,41 chr1:201503249-201503687 downStream 0,099 1,50 
C10orf11 -2,22 0,042 0,69 chr10:76838695-76839061 upStream 0,013 1,50 
CTSC -2,18 0,046 0,63 chr11:87548353-87548640 upStream 0,024 1,85 
RHOQ -2,18 0,046 0,72 chr2:46696964-46697947 upStream 0,006 3,21 
AK2 -2,15 0,049 0,73 chr1:33319679-33319945 downStream 0,029 1,50 
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Table 4. ETS1 under-expressed targets involved in deregulated pathways in low-risk MDS patients.
       
Category  p- Value Number of Genes Molecules  
Cell Death  7,62E-03 - 4,13E-02 9 
IL7R, ITGAL, LCK, MAP4K1, PAK2,  
PTAFR, TNFSF13, TOPBP1, TRADD 
Cellular Function and Maintenance  9,03E-05 - 4,62E-02 6 
IL7R, ITGAL, LCK, MAP4K1, ZAP70,  
FOXP1 
Hematological System Development 
and Function 
1,45E-04 - 4,62E-
02 6 
IL7R, ITGAL, LCK, MAP4K1, ZAP70,  
TNFSF13 
Cellular Development  1,47E-03 - 4,62E-02 6 
IL7R, ITGAL, LCK, MAP4K1, ZAP70,  
LPP 
Hematopoiesis 1,47E-03 - 4,62E-02 5 IL7R, ITGAL, LCK, MAP4K1, ZAP70 
Cell-To-Cell Signaling and Interaction 9,03E-05 - 3,46E-02 4 FOXP1, ITGAL, ZAP70, LCK 
Cell-mediated Immune Response 1,45E-04 - 4,62E-02 4 IL7R, LCK, MAP4K1, ZAP70 
Genetic Disorder 5,43E-03 - 2,12E-02 4 ATXN1, ITGAL, MAP4K1,  TRADD 
Molecular Transport 7,01E-03 - 3,65E-02 4 LCK, TRAT1, ZAP70, PATAFR 
Gene Expression 2,89E-04 - 4,99E-02 3 LCK, ZAP70,  LEF1 
Cellular Growth and Proliferation 6,63E-03 - 1,49E-02 3 IL7R, TNFSF13, ZAP70 
Cell Morphology 7,01E-03 - 4,81E-02 3 LCK, LPP, ZAP70 
Cellular Assembly and Organization 7,01E-03 - 4,81E-02 3 LCK, PTAFR, ZAP70 
Cancer 8,50E-03 2 LCK, ZAP70 
Cell Cycle 7,01E-03 1 PTAFR 
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